All In Biotech

Drug Trial Radar · NCT07580716

Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

182

Planned (sponsor's estimate)

Start

May 1, 2026

Primary completion

Feb 2027

Study completion Apr 2028

Sponsor

Lead sponsor
Enlivex Therapeutics Ltd.Industry
Sponsor type
Industry
Collaborators
Nordic Bioscience Clinical Development
First posted
May 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, Phase IIb study to evaluate intra-articular (IA) injections of Allocetra in participants with moderate-to-severe age related symptomatic primary knee osteoarthritis (OA).

Conditions

  • Primary Knee Osteoarthritis

Interventions

  • AllocetraDrug

    Allocetra is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state.

  • PlaceboOther

    The control used in this study will be placebo. Placebo solution containing all excipients except for the Allocetra cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain score at 3 monthsTime frame: 3 months.
  2. Western Ontario and McMaster Universities Arthritis Index (WOMAC) Function score at 3 monthsTime frame: 3 months.
  3. Primary Safety EndpointTime frame: Day 0 to 6 months.

Locations

17 sites in 3 countries. Site status is shown where the registry gives one.

  • Future Medical Research

    Longwood, Florida · Recruiting

  • South Florida Research Phase I-IV

    Miami, Florida · Recruiting

  • DelRicht Research @ Touro Medical Center

    New Orleans, Louisiana · Recruiting

  • Oakland Medical Research

    Troy, Michigan · Recruiting

  • Sanos Clinic Gandrup

    Gandrup, Denmark · Recruiting

  • Sanos Clinic Herlev

    Herlev, Denmark · Recruiting

  • Sanos Clinic Vejle

    Vejle, Denmark · Recruiting

  • NZOZ Bif-Med. s.c

    Bytom, Poland · Recruiting

  • Vita Longa Sp. z o.o.

    Katowice, Poland · Recruiting

  • Centrum Medyczne PLEJADY

    Krakow, Poland · Not yet recruiting

  • Medyczne Centrum Hetmańska

    Poznan, Poland · Recruiting

  • Reumedika sp. z o.o.

    Poznan, Poland · Recruiting

  • DC-MED Michal Kowalski S.K. Radom

    Radom, Poland · Not yet recruiting

  • DC-MED Michal Kowalski S.K. Swidnica

    Swidnica, Poland · Recruiting

  • Etg Justmed

    Warsaw, Poland · Recruiting

  • Etg Warszawa

    Warsaw, Poland · Recruiting

  • Migre Polskie Centrum

    Wroclaw, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.